Received Aug 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | W014513 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Unknown | — |
Pharmacist reported that a patient received first dose (w014513 exp 1/26/2025) of GARDASIL 9 on 7/18/2024 and the second dose (z018414 exp 12/11/2025) on 7/15/2025. No additional AEs were reported, no further information provided. No PQC.; no additional adverse event; Information has been received from Business Partner/CRO on 15-Jul-2025. This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 18-Jul-2024, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (lot #W014513, expiration date: 26-Jan-2025), dose number 1, for an unknown indication. On 15-Jul-2025, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (lot #Unknown), dose number 2, (indication and expiration date were not reported) (Inappropriate schedule of vaccine administered). No additional adverse event was reported.